Expert consensus on the establishment and clinical application of patient-derived endometrial cancer organoids

Endometrial cancer (EC), the second most common gynaecologic malignancy, faces challenges in precision treatment due to limited predictive models for therapy selection. Patient-derived organoids, which recapitulate tumour heterogeneity and microenvironment, offer a transformative platform for drug sensitivity testing and personalised therapy. However, standardised protocols for establishing EC organoids, biobanking and clinical translation remain lacking consensus. This expert consensus proposes guidelines for EC organoid culture optimisation, characterisation and clinical validation. By harmonising technological advances with clinical needs, this consensus aims to accelerate the integration of organoid models into EC precision medicine, ultimately improving therapeutic outcomes.